Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cancer-associated biomarkers are biological molecules or characteristics found in blood, tissues, or other body fluids that indicate the presence of cancer or provide information about its behavior (National Cancer Institute: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker). These markers include a diverse array of molecules such as proteins, DNA mutations, RNA expression patterns, and metabolites (NIH BEST Resource: https://www.ncbi.nlm.nih.gov/books/NBK338448/). They are essential tools in modern oncology for screening, diagnosing specific cancer types, and determining the prognosis of a patient (Nature Reviews Cancer: https://www.nature.com/articles/nrc.2017.74). Furthermore, predictive biomarkers are used to identify patients most likely to benefit from specific targeted therapies, such as using HER2 status to guide the use of trastuzumab (American Cancer Society: https://www.cancer.org/cancer/diagnosis-staging/tests/biomarker-tests.html). While some biomarkers are also therapeutic targets, the category as a whole represents the measurable indicators of disease state rather than a single receptor or enzyme. The clinical application of these biomarkers facilitates precision medicine by tailoring treatments to the molecular profile of an individual's tumor (PubMed: 30089180). However, the use of biomarkers is often complicated by issues of sensitivity and specificity, which can lead to false positive or false negative results (StatPearls: https://www.ncbi.nlm.nih.gov/books/NBK559036/). Monitoring changes in biomarker levels over time also allows clinicians to assess treatment efficacy and detect early signs of recurrence (Journal of Clinical Oncology: https://ascopubs.org/journal/jco).
Mechanisms of action are specific to the individual biomarker being targeted; they include inhibition of receptor tyrosine kinases, blockade of immune checkpoints, and modulation of hormone receptors (PubMed: 28930210).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cancer-associated biomarkers.